Business Strategy & Outlook
After a tumultuous few years, Becton, Dickinson is undergoing course correction. The COVID-19 revenue windfall has been reinvested, which should lift the firm’s core business growth in the upcoming years once the testing revenue fades. The biggest uncertainty remains around the return of BD’s pump infusion system (Alaris) to the market, which could be a material catalyst for the company whenever it occurs. Historically, BD was considered a virtually recession-proof business. The essential nature of many of BD’s medical products had typically shielded the firm from any capital spending-related volatility, and this business continued to fare fine during the COVID-19-induced hospital admission deceleration. However, many of the businesses acquired with Bard have exposed BD to revenue volatility. Combined with the setbacks and revenue deceleration in the peripheral segment, the Bard acquisition has not been a smashing success. With hospital activity returning to more normal levels, there’s a momentum in the surgery segment that came with Bard, and while peripheral is no longer the star of the portfolio, businesses acquired are lifting BD’s growth profile from its historic levels.
Alaris continues to be a headache for BD, and this recall represents a significant blemish on the company’s previously very clean execution track record. The magnitude of the damage to the pump franchise is still not certain, but BD will still end up ceding material market share in this area by the time the pump returns to the market (which could be as far out as 2025). The company needs almost flawless execution in the upcoming years to reverse investors’ growing skepticism regarding its performance.
Financial Strengths
BD’s debt level is manageable after the Embecta spinoff and recent acquisition. The company has recovered its investment-grade rating and generates strong free cash flow to fund its dividend, which is among the largest of its peers. Most of the COVID-19 testing revenue has been reinvested into R&D, which will lead to an improved growth profile going forward.
Bulls Say
- BD’s surgery business delivered strong performance since the pandemic waned.
- BD reinvested its testing windfall into R&D in its key areas, which will likely lead to the elevated growth (relative to its historic levels) going forward.
- Embecta spinoff is a positive development for BD in terms of its growth opportunities.
Company Description
Becton, Dickinson is the world’s largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company’s business.
(Source: Morningstar)
DISCLAIMER for General Advice: (This document is for general advice only).
This document is provided by Laverne Securities Pty Ltd T/as Laverne Investing. Laverne Securities Pty Ltd, CAR 001269781 of Laverne Capital Pty Ltd AFSL No. 482937.The material in this document may contain general advice or recommendations which, while believed to be accurate at the time of publication, are not appropriate for all persons or accounts. This document does not purport to contain all the information that a prospective investor may require. The material contained in this document does not take into consideration an investor’s objectives, financial situation or needs. Before acting on the advice, investors should consider the appropriateness of the advice, having regard to the investor’s objectives, financial situation, and needs. The material contained in this document is for sales purposes. The material contained in this document is for information purposes only and is not an offer, solicitation or recommendation with respect to the subscription for, purchase or sale of securities or financial products and neither or anything in it shall form the basis of any contract or commitment. This document should not be regarded by recipients as a substitute for the exercise of their own judgment and recipients should seek independent advice. The material in this document has been obtained from sources believed to be true but neither Laverne and Banyan Tree nor its associates make any recommendation or warranty concerning the accuracy or reliability or completeness of the information or the performance of the companies referred to in this document. Past performance is not indicative of future performance. Any opinions and or recommendations expressed in this material are subject to change without notice and, Laverne and Banyan Tree are not under any obligation to update or keep current the information contained herein. References made to third parties are based on information believed to be reliable but are not guaranteed as being accurate.
Laverne and Banyan Tree and its respective officers may have an interest in the securities or derivatives of any entities referred to in this material. Laverne and Banyan Tree do and seek to do business with companies that are the subject of its research reports. The analyst(s) hereby certify that all the views expressed in this report accurately reflect their personal views about the subject investment theme and/or company securities.
Although every attempt has been made to verify the accuracy of the information contained in the document, liability for any errors or omissions (except any statutory liability which cannot be excluded) is specifically excluded by Laverne and Banyan Tree, its associates, officers, directors, employees, and agents. Except for any liability which cannot be excluded, Laverne and Banyan Tree, its directors, employees and agents accept no liability or responsibility for any loss or damage of any kind, direct or indirect, arising out of the use of all or any part of this material. Recipients of this document agree in advance that Laverne and Banyan Tree are not liable to recipients in any matters whatsoever otherwise; recipients should disregard, destroy or delete this document. All information is correct at the time of publication. Laverne and Banyan Tree do not guarantee reliability and accuracy of the material contained in this document and are not liable for any unintentional errors in the document.
The securities of any company(ies) mentioned in this document may not be eligible for sale in all jurisdictions or to all categories of investors. This document is provided to the recipient only and is not to be distributed to third parties without the prior consent of Laverne and Banyan Tree.